Speaker Profile
Ph.D., Chief Technical Officer, DELFI Diagnostics
Biography
Amoolya Singh is Chief Technology Officer at DELFI Diagnostics. Previously, she was Senior Vice President of Research and Chief Scientific Officer at GRAIL, and prior to that, she was Head of Discovery at Calico Life Sciences, where she catalyzed multiple productive collaborations between computational groups and experimental groups. Amoolya earned a PhD in computational biology and a MS in computer science at the University of California at Berkeley. She holds a BS degree in biology and computer science from Carnegie Mellon. Amoolya completed a postdoctoral fellowship at the European Molecular Biology Lab in Heidelberg, Germany in 2008 and a Computational and Life Sciences fellowship at Emory University in 2011 in comparative genomics and metagenomics, population genetics and experimental evolution.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins University
PMWC Award Ceremony
• Klaus Pantel, University Medical Center Hamburg-Eppendorf / ELBS
• Daniel De Carvalho, University of Toronto
Keynote: Early Detection of Cancer by Multimodal Liquid Biopsy Analysis
• Klaus Pantel, UKE / ELBS
From Mutation to Methylation: The Next Wave of Liquid Biopsy Biomarkers
• Chair: Victor Velculescu, Johns Hopkins University
• Daniel De Carvalho, University of Toronto
• Manel Esteller, Sant Pau Research Institute
• Gordon Sanghera, Oxford Nanopore Technologies
Advancing Minimal Residual Disease Detection Through cfDNA & cfRNA Profiling
• Chair: Luis Diaz, Memorial Sloan Kettering Cancer Center
• Anne-Renee Hartman, Adela
• Klaus Pantel, UKE / ELBS
AI-Informed Biomarker Trials: Turning Early Signals into Actionable Designs
• Chair: Manish Kohli, University of Utah
• Luis Diaz, MSKCC
• Eric Klein, GRAIL
• Peter Bach, DELFI Diagnostics
• Samuel Levy, ClearNote Health
Role of AI in Liquid Biopsies & Cancer Detection
• Chair: Amoolya Singh, DELFI Diagnostics
• Matthew Baker, Dxcover
• Pankaj Vats, NVIDIA
Fragmentomics for Early Detection
• Varsha Rao, Claret Bioscience
Integrating Genetic Risk with Early Detection
• Giordano Botta, Allelica
Metagenomic Diagnostics & Global Pathogen Surveillance
• Charles Chiu, UCSF
AI-Driven Host–Pathogen Signatures from Plasma cfDNA
• Sivan Bercovici, Karius
Ultra-Sensitive Multimodal Liquid Biopsy for Early Cancer Detection
• Atul Sharan, CellMax Life
AI-Enhanced Proteomic Signatures for Early Cancer Detection
• Diana Abdueva, Aqtual
